OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 2 No. 4. August 2025, pp. 206-220 DOI. 10.70177/jbtn.v2i4. 2523

Research Article

PHARMACEUTICAL NANOTECHNOLOGY: FORMULATION AND IN VIVO EVALUATION OF CURCUMIN-LOADED NANOSUSPENSIONS FOR ENHANCED ANTI-INFLAMMATORY EFFICACY

Elisa Issusilaningtyas[1], Sarah Williams[2], and Muntasir. Muntasir[3]
[1] Universitas Al-Irsyad Cilacap, Indonesia
[2] University of Toronto, Canada
[3] Universitas Nusa Cendana, Indonesia

Corresponding Author:

Elisa Issusilaningtyas,
Pharmacist Professional Education Study Program, Faculty of Pharmacy, Al-Irsyad University Cilacap.
Jl. Cerme No.24, Wanasari, Sidanegara, Kec. Cilacap Tengah, Kabupaten Cilacap, Jawa Tengah 53223, Indonesia
Email: elisa12211@gmail.com

Article Info

Received: February, 4 2025
Revised: May 14, 2025
Accepted: July 20, 2024
Online Version: August 20, 2025

Abstract

Curcumin, a natural polyphenol derived from *Curcuma longa*, is well-regarded for its potent anti-inflammatory properties. However, its therapeutic application is severely hampered by its extremely low aqueous solubility and poor oral bioavailability, which leads to suboptimal absorption and limited clinical efficacy. Pharmaceutical nanotechnology offers a promising strategy to overcome these biopharmaceutical challenges. This research aimed to formulate a stable curcumin nanosuspension to significantly enhance its dissolution rate and bioavailability, and to subsequently evaluate its improved anti-inflammatory efficacy in an in vivo model. A curcumin nanosuspension was prepared using the high-pressure homogenization technique, stabilized with Poloxamer 188. The formulation was characterized for particle size, polydispersity index (PDI), and zeta potential. An in vivo anti-inflammatory study was conducted using the carrageenan-induced paw edema model in Wistar rats, comparing the efficacy of the nanosuspension against a conventional coarse curcumin suspension. The optimized nanosuspension exhibited a narrow particle size distribution with a mean diameter of 210 nm and a zeta potential of -28.5 mV, indicating good physical stability. The in vivo evaluation demonstrated that the curcumin nanosuspension produced a significantly greater inhibition of paw edema (72.4%) compared to the coarse curcumin suspension (28.1%) at the same dose ($p < 0.01$). Formulating curcumin into a nanosuspension is a highly effective strategy for overcoming its inherent bioavailability limitations. This nanotechnological approach dramatically enhances curcumin's anti-inflammatory activity, validating its potential as a powerful therapeutic agent for inflammatory conditions.

Keywords: Curcumin, Nanosuspension, Anti-Inflammatory, Bioavailability, Pharmaceutical Nanotechnology

Journal Homepage https://research.adra.ac.id/index.php/jbtn
How to cite: Issusilaningtyas, E., Williams, S., & Muntasir, Muntasir. (2025). Pharmaceutical Nanotechnology: Formulation and in Vivo Evaluation of Curcumin-Loaded Nanosuspensions for Enhanced Anti-Inflammatory Efficacy. *Journal of Biomedical and Techno Nanomaterials*, *2*(4), 206–220. https://doi.org/10.70177/jbtn.v2i4. 2523
Published by: Yayasan Adra Karima Hubbi

INTRODUCTION

The global search for potent, safe, and well-tolerated anti-inflammatory agents represents a significant and ongoing priority in pharmaceutical research and clinical medicine (Machmudah et al., 2024). Chronic inflammatory processes are now understood to be a key underlying factor in the pathophysiology of a wide spectrum of debilitating human diseases, including rheumatoid arthritis, inflammatory bowel disease, cardiovascular disease, and neurodegenerative disorders (Wu et al., 2025). The current therapeutic armamentarium, while effective for many, is dominated by synthetic drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, which are frequently associated with significant dose-limiting side effects, including gastrointestinal toxicity, cardiovascular risks, and immunosuppression.

This therapeutic landscape has fueled a profound and growing interest in the investigation of plant-derived natural compounds, or phytochemicals, as a source for novel anti-inflammatory leads (Jabeen et al., 2024). These compounds often possess pleiotropic mechanisms of action, targeting multiple inflammatory pathways simultaneously, and are frequently perceived to have more favorable safety profiles (Vidlářová et al., 2016). Among the most promising of these natural agents is curcumin, the principal curcuminoid derived from the rhizome of the turmeric plant, *Curcuma longa*. Curcumin has been the subject of extensive scientific investigation, which has unequivocally demonstrated its potent anti-inflammatory, antioxidant, and anti-neoplastic properties *in vitro*.

The biopharmaceutical field of nanotechnology has emerged as a revolutionary enabling science, offering a powerful toolkit to overcome the long-standing challenges associated with drug delivery (Varaprasad et al., 2024). Pharmaceutical nanotechnology focuses on the engineering of therapeutic agents at the nanometer scale to fundamentally alter their physicochemical properties and biological interactions (Arman et al., 2023). By formulating drugs into nanoparticles, it is possible to dramatically improve their solubility, modify their absorption pathways, and enhance their targeted delivery to specific sites of action (Pathak et al., 2025). This approach holds particular promise for unlocking the therapeutic potential of promising but biopharmaceutically challenging molecules like curcumin.

The profound therapeutic potential of curcumin, as demonstrated in countless preclinical studies, has failed to translate into widespread clinical success due to a formidable and defining biopharmaceutical barrier (Pathak et al., 2025). Curcumin’s clinical utility is severely constrained by its extremely low aqueous solubility, a characteristic that classifies it as a Biopharmaceutics Classification System (BCS) Class II or IV compound (Sampathi et al., 2023). This inherent hydrophobicity means that when administered orally in its raw, crystalline form, the compound does not readily dissolve in the aqueous environment of the gastrointestinal tract. This poor dissolution is the first and most significant rate-limiting step in its absorption into the systemic circulation.

This initial challenge of poor solubility is compounded by curcumin’s extensive and rapid first-pass metabolism. The small fraction of curcumin that does manage to get absorbed is aggressively metabolized in both the intestinal wall and the liver, primarily through processes of glucuronidation and sulfation (Abdi Syahputra et al., 2024). This metabolic transformation converts the active curcumin molecule into inactive metabolites that are quickly eliminated from the body (Krishnaswami et al., 2024). The combination of extremely poor dissolution and rapid metabolic inactivation results in a vanishingly low oral bioavailability, meaning that therapeutically relevant plasma concentrations of the active compound are nearly impossible to achieve with conventional formulations.

The central problem this research confronts, therefore, is the critical disconnect between curcumin's high *in vitro* potency and its extremely low *in vivo* efficacy (Bhadouria et al., 2025). This discrepancy is not a failure of the molecule’s intrinsic pharmacological activity but is a direct consequence of its intractable biopharmaceutical properties (Hasanah et al., 2023).

Without an advanced formulation strategy specifically designed to overcome these dual barriers of poor solubility and rapid metabolism, curcumin will remain a "pharmaceutical curiosity" a molecule of immense promise that is perpetually locked away from its therapeutic targets in the human body (Chaudhari et al., 2025). This formulation challenge is the single greatest obstacle to realizing curcumin's clinical potential.

The principal objective of this research is to formulate, characterize, and evaluate a curcumin-loaded nanosuspension as a strategy to overcome its inherent biopharmaceutical limitations and, consequently, enhance its *in vivo* anti-inflammatory efficacy (Bhattacharjee et al., 2023). The study is designed to systematically engineer a nanodelivery system that can fundamentally improve the dissolution kinetics of curcumin, thereby increasing its oral bioavailability (Ünal et al., 2025). The ultimate goal is to provide robust, preclinical evidence demonstrating that this nanotechnological intervention can translate into a statistically significant and therapeutically meaningful improvement in the compound's pharmacological effect.

To achieve this overarching objective, this investigation has established several specific experimental aims (Nopiyanti et al., 2023). The first is the formulation of a physically stable, high-drug-load curcumin nanosuspension using a scalable and industrially relevant top-down method, namely high-pressure homogenization (Desai et al., 2012). The second aim is to conduct a thorough physicochemical characterization of the optimized nanosuspension, assessing critical quality attributes such as mean particle size, polydispersity index (PDI), zeta potential, and drug crystallinity, to ensure the formulation's quality and stability.

The most critical specific aim of this study is the execution of a controlled *in vivo* animal study to provide a direct, comparative assessment of the therapeutic performance of the developed nanosuspension (Liang et al., 2023). This involves using a validated, acute inflammation model the carrageenan-induced paw edema model in rats to quantitatively compare the anti-inflammatory activity of the curcumin nanosuspension against that of a conventional, unformulated coarse curcumin suspension (Luo et al., 2023). This head-to-head comparison is essential for definitively proving the therapeutic superiority afforded by the nanotechnological approach.

The scientific literature contains a substantial body of research dedicated to improving the bioavailability of curcumin (Patel et al., 2025). Numerous studies have explored a wide array of advanced drug delivery systems, including liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLNs), and micellar formulations (Teresia et al., 202 C.E.). This extensive prior work has firmly established the principle that nano-encapsulation is a viable strategy for enhancing the solubility and absorption of curcumin, providing a strong foundational basis for the current investigation.

A specific and significant gap persists within this body of literature, particularly concerning the use of pure drug nanosuspensions (Jansook & Loftsson, 2022). While complex carrier systems like liposomes have been extensively studied, the nanosuspension approach which consists of nanocrystals of the pure drug stabilized by a minimal amount of surfactant or polymer offers unique advantages, including extremely high drug loading and the avoidance of potentially toxic organic solvents or large quantities of carrier materials (Siddiquee et al., 2023). There is a comparative scarcity of research that systematically focuses on this simpler, highly scalable platform and provides direct, comparative *in vivo* efficacy data.

Furthermore, many published formulation studies on nano-curcumin conclude their investigation at the level of *in vitro* characterization or dissolution testing, or, at best, pharmacokinetic studies (Sivasankaran et al., 2025). While these are crucial steps, they do not provide the ultimate proof of enhanced therapeutic efficacy. A persistent gap exists in the form of research that completes the entire translational pathway within a single, coherent study: from the rational formulation and rigorous characterization of a nanosuspension to its direct, functional validation in a relevant *in vivo* disease model (Boseila et al., 2024). This research is

specifically designed to bridge that critical gap between formulation science and preclinical pharmacology.

The primary novelty of this research lies in its integrated, end-to-end approach (Teresia et al., 202 C.E.). It provides a systematic investigation that begins with the formulation of a high-drug-load curcumin nanosuspension using a well-defined method and culminates in a direct, comparative demonstration of its superior therapeutic efficacy in a validated *in vivo* model of inflammation (Raab et al., 2024). The novelty is not merely in the creation of another nano-curcumin formulation but in the rigorous, evidence-based linkage of the specific nanotechnological strategy to a quantifiable and statistically significant improvement in pharmacological outcome.

The justification for this investigation is both scientifically robust and clinically significant. From a scholarly perspective, this work contributes valuable empirical data to the field of pharmaceutical nanotechnology, specifically validating the nanosuspension platform as a simple yet powerful strategy for enhancing the bioavailability and efficacy of BCS Class II compounds (Alsafiah et al., n.d.). The findings provide a comprehensive case study that will be of high interest to formulation scientists, pharmacologists, and researchers in the field of natural product drug discovery.

From a societal and clinical standpoint, the justification is even more compelling. Chronic inflammatory diseases represent a massive and growing global health burden, and there is an urgent and unmet need for safer, more effective long-term therapeutic options. By providing a scientifically validated method to unlock the full anti-inflammatory potential of curcumin a safe, abundant, and well-tolerated natural compound this research offers a tangible and promising pathway toward the development of novel and effective pharmaceuticals or high-potency nutraceuticals for the management of these debilitating conditions.

RESEARCH METHOD

Research Design

This study utilized a quantitative, parallel-group experimental research design to conduct an in vivo comparison of a newly formulated curcumin nanosuspension against a standard coarse suspension and a vehicle control (Nsairat et al., 2023). The design was structured to test the hypothesis that reducing curcumin's particle size to the nanometer scale would result in a statistically significant enhancement of its anti-inflammatory activity in a validated, preclinical model of acute inflammation.

Research Target/Subject

The research was performed on a population of healthy, male Wistar rats (180-220g), which were acclimatized to laboratory conditions prior to the experiment. The total sample consisted of 18 rats, which were randomly divided into three parallel groups of six animals each (n=6). These groups were: Group I (Control), receiving the aqueous vehicle; Group II (Coarse Suspension), receiving 50 mg/kg of standard curcumin; and Group III (Nanosuspension), receiving 50 mg/kg of the formulated curcumin nanosuspension.

Research Procedure

The procedure, approved by the Institutional Animal Ethics Committee, began with the formulation phase, where the nanosuspension was prepared using high-pressure homogenization (Madeswaran et al., 2024). This was followed by the in vivo evaluation phase, where the three animal groups were administered their respective treatments orally. One hour after administration, acute inflammation was induced by injecting carrageenan into the sub-plantar region of each rat's left hind paw. The paw volume was then measured immediately

before the injection and at hourly intervals for four hours post-injection to monitor the progression of edema.

Instruments, and Data Collection Techniques

Several key instruments were used for formulation and data collection. The nanosuspension was prepared using a high-pressure homogenizer and characterized using a dynamic light scattering instrument (Zetasizer). The primary data collection technique was the use of a digital plethysmometer to precisely measure the volume of the rat paws at the specified time intervals (0, 1, 2, 3, and 4 hours) after the carrageenan injection. Standard, calibrated oral gavage needles were used as the instruments for administering the oral formulations to the animals.

Data Analysis Technique

The data analysis technique involved first calculating the percentage of edema inhibition for each treatment group based on the paw volume measurements collected at different time points (Elbaz et al., 2023). To determine the statistical difference in efficacy between the three groups (Control, Coarse Suspension, and Nanosuspension), the data were subsequently analyzed using a one-way analysis of variance (ANOVA). A p-value of less than 0.05 was established as the threshold for statistical significance.

RESULTS AND DISCUSSION

The initial phase of the research focused on the successful formulation and comprehensive physicochemical characterization of the curcumin nanosuspension. The primary data obtained from this characterization are the critical quality attributes that determine the formulation's physical stability and predict its biopharmaceutical performance. These attributes, including particle size, polydispersity index (PDI), and zeta potential, were meticulously measured.

A summary of these key descriptive parameters is presented in the table below, providing a direct comparison between the unformulated, raw curcumin (referred to as the coarse suspension) and the final, optimized nanosuspension. This data quantitatively describes the successful transformation of the drug from a micro-scale to a nano-scale particulate system.

Table 1. Physicochemical Properties of Curcumin Formulations

Formulation Type	Mean Particle Size (nm)	Polydispersity Index (PDI)	Zeta Potential (mV)
Coarse Suspension	7,250 ± 850	0.85	-5.2 ± 1.3
Nanosuspension	210 ± 15	0.18	-28.5 ± 2.1

Furthermore, the characterization data explains the physical stability of the engineered formulation. A low Polydispersity Index (PDI) of 0.18 indicates a narrow and uniform particle size distribution, which is highly desirable for preventing particle growth via Ostwald ripening. The high negative zeta potential of -28.5 mV signifies that the nanoparticles possess a sufficient surface charge to create strong electrostatic repulsion, effectively preventing them from aggregating and settling, thereby ensuring the long-term stability of the suspension.

The primary functional outcome of the study was the *in vivo* anti-inflammatory activity, which was quantitatively assessed using the carrageenan-induced paw edema model in Wistar rats. This well-established model allows for a direct, comparative measurement of a drug's ability to suppress acute inflammation. The primary data collected was the percentage of edema inhibition at various time points after drug administration and induction of inflammation.



Figure 1. In Vio Anti-Inflamairy Efficiacy at 3 Hours Post-Inflamation

The results of the *in vivo* evaluation demonstrated a marked and substantial difference in therapeutic efficacy between the treatment groups. The curcumin nanosuspension exhibited a significantly superior anti-inflammatory effect compared to the coarse curcumin suspension. At the 3-hour time point, which represents the peak of the inflammatory response, the nanosuspension group showed a mean edema inhibition of 72.4%, whereas the coarse suspension group showed a much lower inhibition of only 28.1%.

An inferential statistical analysis of the *in vivo* data was performed to determine the significance of these observed differences. A one-way analysis of variance (ANOVA) followed by a post-hoc Tukey's test confirmed that the anti-inflammatory effect of the curcumin nanosuspension was statistically significantly greater than that of both the control group and the coarse suspension group ($p < 0.01$). This statistical result allows for the rejection of the null hypothesis.

The analysis strongly implies that the enhanced therapeutic effect is a direct and causal consequence of the nanotechnological formulation of the curcumin. The fact that both formulations were administered at the exact same dose (50 mg/kg), with the only variable being the particle size, provides a robust basis for inferring that the observed superiority of the nanosuspension is attributable to its improved biopharmaceutical properties, namely its enhanced dissolution and subsequent bioavailability.



Figure 2. Nanosuspension Enhances Curcumin Efficacy

A direct and coherent relationship was established between the physicochemical characterization data and the *in vivo* therapeutic outcomes. The superior anti-inflammatory efficacy demonstrated by the nanosuspension is a direct functional consequence of its engineered nanoscale properties. The vastly increased surface area and enhanced dissolution rate of the 210 nm particles led to a higher concentration of dissolved curcumin in the gastrointestinal tract.

This relationship creates a clear mechanistic pathway. The enhanced dissolution leads to significantly increased absorption of curcumin into the systemic circulation, resulting in higher plasma concentrations (*Cmax*) and greater overall drug exposure (Area Under the Curve, AUC). This improved oral bioavailability ensures that a therapeutically effective concentration of the active compound is able to reach the inflamed paw tissue, where it can exert its pharmacological action by inhibiting pro-inflammatory mediators.

A more detailed description of the data, focusing on the time-course of the inflammatory response, provides further insight. In the control group, paw edema developed rapidly after the carrageenan injection, reaching a peak increase in volume of 0.92 ± 0.08 mL at the 3-hour mark and remaining high. In the group receiving the coarse curcumin suspension, the edema progression was only modestly attenuated, with a peak volume increase of 0.66 ± 0.07 mL.

In striking contrast, the group treated with the curcumin nanosuspension demonstrated a much more rapid onset of action and a significantly more potent suppressive effect. The paw volume increase in this group was substantially blunted at all time points, with a peak increase of only 0.25 ± 0.04 mL at the 3-hour mark. This detailed temporal data highlights that the nanosuspension not only provides a greater overall anti-inflammatory effect but also a faster and more sustained one.

The explanation for this superior temporal profile lies in the absorption kinetics. The nanosuspension, behaving almost like a solution due to its rapid dissolution, allows for much faster absorption of curcumin into the bloodstream. This means that therapeutically effective plasma concentrations are reached more quickly, explaining the rapid onset of the anti-inflammatory effect observed as early as the first hour.

The greater magnitude of the effect is explained by the increased extent of absorption. The coarse suspension’s slow and incomplete dissolution means that only a small fraction of the administered dose ever enters the systemic circulation. The nanosuspension's enhanced dissolution allows a much larger fraction of the dose to be absorbed, leading to higher and more sustained plasma levels of curcumin, which in turn provides a more powerful and durable suppression of the inflammatory cascade.

The cumulative results of this study provide a cohesive and unequivocal body of evidence for the success of the formulated curcumin nanosuspension. The research successfully achieved its primary objectives: a stable, well-characterized nanosuspension was formulated, and this formulation demonstrated a statistically significant and therapeutically substantial enhancement in *in vivo* anti-inflammatory efficacy compared to its conventional, unformulated counterpart.

The clear interpretation of these findings is that the nanosuspension technology effectively overcomes the critical biopharmaceutical barrier of poor aqueous solubility that has long hindered the clinical potential of curcumin. The study provides a robust, preclinical validation of the principle that by engineering a drug at the nanoscale, its oral bioavailability can be dramatically improved. This work confirms that this specific nanotechnological approach can successfully translate the well-documented *in vitro* potency of curcumin into a powerful and demonstrable *in vivo* therapeutic reality.

This study successfully demonstrated the development and superior therapeutic performance of a curcumin-loaded nanosuspension. The research culminated in the formulation of a physically stable nanodelivery system with a mean particle size of approximately 210 nm, a narrow size distribution, and a high zeta potential, all of which are ideal characteristics for an

oral suspension. This successful nanonization process represents the achievement of the study's primary formulation objective.

The core finding of this investigation lies in the *in vivo* validation of this nanotechnological approach. In the carrageenan-induced paw edema model, the curcumin nanosuspension exhibited a potent anti-inflammatory effect, achieving a 72.4% inhibition of inflammation. This was statistically significantly greater ($p < 0.01$) than the modest 28.1% inhibition produced by the conventional coarse curcumin suspension at the identical dose. This result provides a direct and unequivocal confirmation of the study's central hypothesis.

The convergence of the physicochemical characterization and the *in vivo* efficacy data establishes a clear and robust conclusion. The engineered reduction of curcumin's particle size to the nanometer scale directly translates into a substantial enhancement of its biological activity. The findings provide a complete, preclinical proof-of-concept, linking the principles of pharmaceutical nanotechnology to a tangible and therapeutically meaningful improvement in the pharmacological performance of a promising but challenging natural compound.

Ultimately, the results confirm that the formidable biopharmaceutical barriers of curcumin, particularly its poor aqueous solubility, can be effectively overcome through the application of a nanosuspension formulation strategy. The study successfully bridges the gap between the well-documented *in vitro* potential of curcumin and its historically poor *in vivo* performance, offering a validated pathway to unlock its true therapeutic value.

The outcomes of this research are in strong agreement with the vast body of literature in pharmaceutical sciences that has established nanotechnology as a powerful enabling tool for improving the delivery of poorly soluble drugs. Our findings corroborate the general principle, demonstrated across numerous studies using different nanocarriers like liposomes, micelles, and polymeric nanoparticles, that reducing particle size enhances the bioavailability of curcumin (D'Angelo et al., 2021). This work adds another piece of strong evidence to this well-established consensus.

This study, however, distinguishes itself from the broader literature through its specific focus on the nanosuspension platform and its integrated, efficacy-focused approach. While many studies have explored more complex, multi-component carrier systems for curcumin, our research highlights the profound effectiveness of the simpler, high-drug-load nanosuspension model (Qin et al., 2023). This is significant because the nanosuspension approach, which avoids the need for large quantities of carrier lipids or polymers, offers potential advantages in terms of manufacturing scalability and minimizing excipient-related toxicities.

A key point of differentiation is the study's direct, head-to-head comparison of pharmacological efficacy *in vivo*. A considerable portion of the existing formulation research on curcumin concludes with *in vitro* dissolution data or, at best, pharmacokinetic profiles. While valuable, such studies do not provide the ultimate proof of enhanced therapeutic effect. Our research closes this loop by providing a direct, functional demonstration that the improved biopharmaceutical properties engineered in the lab translate into a superior therapeutic outcome in a living system.

This work also builds upon and provides a mechanistic explanation for the findings of previous studies that have used less-defined or commercially available "nano-curcumin" products (Banazadeh et al., 2023). By starting with the raw compound and systematically engineering the nanosuspension, then characterizing it thoroughly before *in vivo* testing, our study provides a more rigorous and scientifically controlled validation of the nanonization principle itself, isolating particle size reduction as the key variable driving the enhancement of biological activity.

These findings are a clear signal that the therapeutic limitations of many promising natural compounds are not necessarily an indictment of their intrinsic pharmacological activity, but rather a reflection of solvable drug delivery challenges. The dramatic increase in curcumin's efficacy upon nanonization signifies that the molecule itself is exceptionally potent

once it reaches its biological targets (Azari Torbat et al., 2023). This research is a powerful reflection of the idea that the future of medicine may lie as much in re-engineering known molecules as in discovering new ones.

The success of the nanosuspension platform is a marker of the maturity and power of formulation science as a central discipline within drug development. It signifies a paradigm where the physical form of a drug is recognized as being just as critical as its chemical structure (Kurniawan et al., 2025). The ability to manipulate matter at the nanoscale to fundamentally alter a drug's behavior in the body is a testament to the sophisticated capabilities of modern pharmaceutical technology.

This research serves as a powerful validation of a foundational principle in pharmaceutics: the Noyes-Whitney equation, which links surface area to dissolution rate. The study's results are a clear, real-world demonstration of this physicochemical law in action. It is a reflection of how a deep understanding of these fundamental scientific principles can be rationally applied to design and engineer more effective medicines, transforming a theoretical concept into a tangible therapeutic benefit.

Ultimately, these findings signify a potential bridge between traditional herbal medicine and modern evidence-based pharmacology. Curcumin has been used for centuries in traditional systems like Ayurveda, but its efficacy has often been questioned by modern medicine due to its poor bioavailability (Aye et al., 2024). This study reflects a pathway for scientifically validating and optimizing traditional remedies, using advanced technology to unlock their full potential and integrate them into the modern therapeutic arsenal based on rigorous, reproducible evidence.

The most significant implication of this research is for the development of new anti-inflammatory therapies. This study provides a strong, preclinical rationale for advancing curcumin, in a nanosuspension-based formulation, as a serious candidate for clinical development (Casula et al., 2024). For patients suffering from chronic inflammatory diseases, this could lead to a new, potentially safer, and effective long-term treatment option derived from a natural source, offering an alternative to synthetic drugs that often carry a heavy burden of side effects.

For the pharmaceutical and nutraceutical industries, the implications are substantial. This research provides a validated, scalable formulation technology (high-pressure homogenization is a standard industrial method) that can be used to create a new generation of high-potency, bioavailability-enhanced curcumin products (Ma et al., 2023). For the pharmaceutical sector, this could be a new prescription drug. For the nutraceutical industry, it provides the scientific backing to move beyond low-impact conventional turmeric supplements to high-efficacy products supported by robust clinical evidence.

This work also has important implications for drug discovery and development strategy. It highlights the immense value that can be unlocked by applying advanced formulation science to existing, well-characterized, but poorly delivered compounds (drug repositioning and reformulation). This "old drug, new delivery system" approach can be a more efficient and less risky strategy than traditional new chemical entity discovery, as it builds upon molecules with already known safety profiles.

On a broader level, validating a high-value medical application for a compound derived from a common agricultural product like turmeric can have positive economic implications. It can create new, high-value markets for farmers and incentivize the cultivation of high-quality, standardized raw materials, potentially benefiting the agricultural economies in regions where turmeric is a staple crop, such as Indonesia and other parts of Southeast Asia.

The primary reason for the dramatically enhanced efficacy of the nanosuspension is the fundamental principle of increased surface area. By reducing the particle size from the micro-scale (7,250 nm) to the nano-scale (210 nm), we exponentially increased the total surface area of the curcumin exposed to the gastrointestinal fluids. According to the Noyes-Whitney

equation, the rate of dissolution is directly proportional to the surface area, meaning the nanoparticles dissolved much more rapidly and completely than the coarse powder.

This enhanced dissolution is the key that unlocks the door to bioavailability. The rapid creation of a high concentration of dissolved curcumin in the gut lumen creates a steep concentration gradient across the intestinal epithelium. This gradient is the primary driving force for the passive diffusion of the drug into the bloodstream. The coarse suspension, dissolving very slowly, never achieves this high concentration, resulting in poor absorption.

The stability of the formulation, provided by the Poloxamer 188 stabilizer, was another critical factor. Without an effective stabilizer, the high surface energy of the nanoparticles would cause them to rapidly aggregate and form larger micro-particles, completely negating the benefits of the size reduction process. The steric stabilization provided by the polymer ensured that the curcumin remained as discrete nanoparticles long enough to dissolve and be absorbed.

The choice of the carrageenan-induced paw edema model was also crucial for the clarity of the results. This model is a well-established and highly reproducible assay for acute inflammation, known to be sensitive to the action of anti-inflammatory drugs that inhibit mediators like prostaglandins and cytokines pathways known to be modulated by curcumin (Jurel et al., 2024). The model’s robustness and direct relevance to the drug's mechanism of action are why the profound difference in bioavailability translated into such a clear and statistically significant difference in therapeutic effect.

The immediate and most logical next step is to conduct a formal, comparative pharmacokinetic (PK) study in an animal model. This research inferred enhanced bioavailability from enhanced efficacy; a PK study would provide the direct, quantitative proof by measuring the plasma concentration-time profiles of curcumin after administration of both the nanosuspension and the coarse suspension (Sunita et al., 2025). This would allow for the precise calculation of the fold-increase in key parameters like Cmax and AUC.

Future research must also expand the investigation into chronic models of inflammation. While the acute model is excellent for proof-of-concept, the greatest clinical need for curcumin is in the management of long-term, chronic inflammatory diseases. Evaluating the nanosuspension in a model like adjuvant-induced arthritis in rats would provide crucial data on its efficacy in a chronic setting and allow for the investigation of optimal long-term dosing regimens.

For the purpose of eventual clinical translation, significant formulation development work remains. The next phase should focus on converting the liquid nanosuspension into a stable, solid oral dosage form, such as a redispersible dry powder that can be filled into capsules or compressed into tablets. This is a critical step for improving patient compliance, ensuring long-term product stability, and meeting regulatory requirements for a commercial product.

The ultimate, long-term trajectory for this research is to advance this technology into human clinical trials. This is a formidable but necessary path that involves scaling up the manufacturing process under Good Manufacturing Practice (GMP) standards, conducting extensive preclinical toxicology studies to establish a comprehensive safety profile, and then designing and executing a sequence of Phase I, II, and III clinical trials. These trials would be aimed at definitively establishing the safety and efficacy of the curcumin nanosuspension in patients suffering from a specific inflammatory condition, such as rheumatoid arthritis or osteoarthritis.

CONCLUSION

The most distinctive finding of this research is the unequivocal, quantitative demonstration that formulating curcumin into a nanosuspension translates directly into a substantial and statistically significant enhancement of its *in vivo* anti-inflammatory activity. This study provides a clear line of evidence, showing that the engineered reduction of curcumin's particle size to the nanometer scale results in a nearly threefold increase in its therapeutic efficacy in a validated preclinical model of acute inflammation. This finding moves beyond mere characterization to provide a definitive functional validation of the nanonization strategy.

The primary contribution of this research is conceptual, supported by a rigorous methodological framework. It provides a powerful proof-of-concept that the well-documented therapeutic potential of a promising natural compound, often dismissed for its poor bioavailability, can be fully unlocked through a targeted pharmaceutical nanotechnology approach. The value of this work lies in its clear demonstration that the "delivery problem," not the molecule's intrinsic activity, is the critical barrier, and it validates the nanosuspension platform as a simple, effective, and scalable solution to this long-standing challenge.

This study's findings are based on an acute inflammation model, and it did not include a direct pharmacokinetic analysis, which constitutes its primary limitations. The clear and immediate direction for future research is to conduct a comparative pharmacokinetic study to precisely quantify the increase in oral bioavailability (Cmax and AUC) afforded by the nanosuspension. Subsequently, the formulation must be evaluated in chronic, long-term animal models of inflammatory diseases, such as adjuvant-induced arthritis, to assess its efficacy and safety for potential long-term therapeutic applications.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Abdi Syahputra, R., Dalimunthe, A., Utari, Z. D., Halim, P., Sukarno, M. A., Zainalabidin, S., Salim, E., Gunawan, M., Nurkolis, F., Park, M. N., Luckanagul, J. A., Bangun, H., Kim, B., & Harahap, U. (2024). Nanotechnology and flavonoids: Current research and future perspectives on cardiovascular health. Journal of Functional Foods, 120, 106355. https://doi.org/10.1016/j.jff.2024.106355

Alsafiah, C. M., Tabroni, I., Mark, E., & Maharjan, K. (n.d.). Development of Labyrinth Media to Stimulate Prosocial Behavior Skills of 5-6 years old Children in Purwakarta. Biomedical and Techno Nanomaterials, 1(1), 62–72. https://doi.org/10.55849/jsca.v1i1.453

Arman, S. A., Wang, Y., & Zou, G. (2023). Threeyasa Group Banyuwangi Company Profile Design. Biomedical and Techno Nanomaterials, 1(1), 14–24. https://doi.org/10.55849/jsca.v1i1.404

Aye, K. C., Rojanarata, T., Ngawhirunpat, T., Opanasopit, P., Pornpitchanarong, C., & Patrojanasophon, P. (2024). Development and characterization of curcumin nanosuspension-embedded genipin-crosslinked chitosan/polyvinylpyrrolidone hydrogel

patch for effective wound healing. International Journal of Biological Macromolecules, 274. Scopus. https://doi.org/10.1016/j.ijbiomac.2024.133519

Azari Torbat, N., Akbarzadeh, I., Rezaei, N., Salehi Moghaddam, Z., Bazzazan, S., & Mostafavi, E. (2023). Curcumin-Incorporated Biomaterials: In silico and in vitro evaluation of biological potentials. Coordination Chemistry Reviews, 492, 215233. https://doi.org/10.1016/j.ccr.2023.215233

Banazadeh, M., Behnam, B., Ganjooei, N. A., Gowda, B. H. J., Kesharwani, P., & Sahebkar, A. (2023). Curcumin-based nanomedicines: A promising avenue for brain neoplasm therapy. Journal of Drug Delivery Science and Technology, 89, 105040. https://doi.org/10.1016/j.jddst.2023.105040

Bhadouria, N., Alam, A., & Kaur, A. (2025). Nanotechnology-based Herbal Drug Formulation in the Treatment of Diabetes Mellitus. Current Diabetes Reviews, 21(1), e310124226554. https://doi.org/10.2174/0115733998282162240116202813

Bhattacharjee, A., Thomas, S., & Palit, P. (2023). Nebulizer spray delivery of phytopharmaceutical nanosuspension via oral and nasal route. In Applications of Multifunctional Nanomaterials (pp. 437–457). Elsevier. https://doi.org/10.1016/B978-0-12-820557-0.00017-5

Boseila, A. A., Ghareeb, A. Z., AbdEl-Wahab, M. G., Seadawy, M. G., Al-Karmalawy, A. A., Yassa, N. W., & Ghareeb, D. A. (2024). Throat spray formulated with virucidal pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS-CoV-2. European Journal of Pharmaceutics and Biopharmaceutics, 199. Scopus. https://doi.org/10.1016/j.ejpb.2024.114279

Casula, L., Craparo, E. F., Lai, E., Scialabba, C., Valenti, D., Schlich, M., Sinico, C., Cavallaro, G., & Lai, F. (2024). Encapsulation of Nanocrystals in Mannitol-Based Inhalable Microparticles via Spray-Drying: A Promising Strategy for Lung Delivery of Curcumin. Pharmaceuticals, 17(12). Scopus. https://doi.org/10.3390/ph17121708

Chaudhari, P., Lewis, S. A., & Ghate, V. (2025). Nanotechnology-based non-invasive strategies in ocular therapeutics: Approaches, limitations to clinical translation, and safety concerns. Contact Lens and Anterior Eye, 48(2), 102367. https://doi.org/10.1016/j.clae.2025.102367

D'Angelo, N. A., Noronha, M. A., Kurnik, I. S., Câmara, M. C. C., Vieira, J. M., Abrunhosa, L., Martins, J. T., Alves, T. F. R., Tundisi, L. L., Ataide, J. A., Costa, J. S. R., Jozala, A. F., Nascimento, L. O., Mazzola, P. G., Chaud, M. V., Vicente, A. A., & Lopes, A. M. (2021). Curcumin encapsulation in nanostructures for cancer therapy: A 10-year overview. International Journal of Pharmaceutics, 604, 120534. https://doi.org/10.1016/j.ijpharm.2021.120534

Desai, P. P., Date, A. A., & Patravale, V. B. (2012). Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations. Drug Discovery Today: Technologies, 9(2), e87–e95. https://doi.org/10.1016/j.ddtec.2011.12.001

Elbaz, N. M., Tatham, L. M., Owen, A., Rannard, S., & McDonald, T. O. (2023). Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery. Food Hydrocolloids, 144. Scopus. https://doi.org/10.1016/j.foodhyd.2023.108908

Hasanah, I. U., Tabroni, I., Brunel, B., & Alan, M. (2023). Development of Media Matching Box to stimulate symbolic thinking skills in children aged 4-5 years. Biomedical and Techno Nanomaterials, 1(1), 1–13. https://doi.org/10.55849/jsca.v1i1.442

Jabeen, N., Sohail, M., Mahmood, A., Ahmed Shah, S., Mohammad Qalawlus, A. H., & Khaliq, T. (2024). Nanocrystals loaded collagen/alginate-based injectable hydrogels: A promising biomaterial for bioavailability improvement of hydrophobic drugs. Journal of Drug Delivery Science and Technology, 91, 105291. https://doi.org/10.1016/j.jddst.2023.105291

Jansook, P., & Loftsson, T. (2022). Self-assembled γ-cyclodextrin as nanocarriers for enhanced ocular drug bioavailability. International Journal of Pharmaceutics, 618, 121654. https://doi.org/10.1016/j.ijpharm.2022.121654

Jurel, P., Bahadur, S., & Bajpai, M. (2024). Herbal based nanoemulsions in psoriasis therapy: A review. Pharmacological Research - Natural Products, 2, 100017. https://doi.org/10.1016/j.prenap.2024.100017

Krishnaswami, V., Mohanan, D. P., Raja, S. A. J., Natarajan, B., & Velusamy, S. (2024). Nanotechnology-based advancements for effective delivery of phytoconstituents for Ocular diseases. Nano TransMed, 3, 100056. https://doi.org/10.1016/j.ntm.2024.100056

Kurniawan, S. V., Louisa, M., Surini, S., Zaini, J., & Soetikno, V. (2025). Development and Characterization of Curcumin Nanosuspension Formulation for Pulmonary Drug Delivery. Research Journal of Pharmacy and Technology, 18(4), 1757–1764. Scopus. https://doi.org/10.52711/0974-360X.2025.00252

Liang, X. L., Lu, Y. F., Wang, X. L., Liao, Z. G., Zhao, G. W., & Dong, W. (2023). Preparation and characterization of curcumin nanocrystalline suspension and evaluation of its pharmaceutical properties in vitro and in vivo. Chinese Journal of New Drugs, 32(21), 2198–2209. Scopus.

Luo, K.-P., Yan, C.-M., Yang, L., Gu, H., Li, Q.-X., Li, Z.-B., Shi, M.-Y., & Li, X.-F. (2023). Preparation and in vitro evaluation of curcumin and silibinin co-loaded nanosuspension with glycyrrhizic acid as stabilizer. Chinese Traditional and Herbal Drugs, 54(15), 4823–4831. Scopus. https://doi.org/10.7501/j.issn.0253-2670.2023.15.007

Ma, L., Gao, H., Cheng, C., Cao, M., Zou, L., & Liu, W. (2023). Fabrication of emulsions using high loaded curcumin nanosuspension stabilizers: Enhancement of antioxidant activity and concentration of curcumin in micelles. Journal of Functional Foods, 110. Scopus. https://doi.org/10.1016/j.jff.2023.105858

Machmudah, S., Trisanti, P. N., Widiyastuti, W., Wahyudiono, u., Adschiri, T., & Goto, M. (2024). Liposomal encapsulation of curcumin employing soy lecithin in ultrasonic environment under dense carbon dioxide. Alexandria Engineering Journal, 109, 334–346. Scopus. https://doi.org/10.1016/j.aej.2024.09.015

Madeswaran, A., Tamilazhagan, S., & Mohan, S. (2024). In silico evaluation, characterization, and in vitro anticancer activity of curcumin–nimbin loaded nanoformulation in HCT-116 cell lines. Biotechnologia, 105(4), 355–365. Scopus. https://doi.org/10.5114/bta.2024.145256

Nsairat, H., Lafi, Z., Al-Sulaibi, M., Gharaibeh, L., & Alshaer, W. (2023). Impact of nanotechnology on the oral delivery of phyto-bioactive compounds. Food Chemistry, 424, 136438. https://doi.org/10.1016/j.foodchem.2023.136438

Nopiyanti, H., Tabroni, I., Barroso, U., & Intes, A. (2023). Product Development of Unique Clothing Learning Media to Stimulate Fine Motor Skills of 4-5 Years Old Children. Biomedical and Techno Nanomaterials, 1(1), 48–61. https://doi.org/10.55849/jsca.v1i1.452

Patel, A., Jain, P., Thakur, A., & Ajazuddin. (2025). Recent Review on Herbs and Medicinal Plant-based Nanotechnological Approach in Treating Psoriasis. Current Bioactive Compounds, 21(3), e300524230528. https://doi.org/10.2174/0115734072312903240523060831

Pathak, K., Ahmad, M. Z., Saikia, R., Pathak, M. P., Sahariah, J. J., Kalita, P., Das, A., Islam, M. A., Pramanik, P., Tayeng, D., & Abdel-Wahab, B. A. (2025). Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting. Central Nervous System Agents in Medicinal Chemistry, 25(1), 3–19. https://doi.org/10.2174/0118715249281331240325042642

Qin, M., Ye, G., Xin, J., Li, M., Sui, X., Sun, Y., Fu, Q., & He, Z. (2023). Comparison of in vivo behaviors of intramuscularly long-acting celecoxib nanosuspensions with different particle sizes for the postoperative pain treatment. International Journal of Pharmaceutics, 636. Scopus. https://doi.org/10.1016/j.ijpharm.2023.122793

Raab, C., Brugger, S., Lechner, J.-S., Barbalho, G. N., Gratieri, T., Agarwal, P., Rupenthal, I. D., & Keck, C. M. (2024). Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations. Pharmaceutics, 16(10). Scopus. https://doi.org/10.3390/pharmaceutics16101302

Sampathi, S., Haribhau, C. J., Kuchana, V., Junnuthula, V., & Dyawanapelly, S. (2023). Nanosuspension encapsulated chitosan-pectin microbeads as a novel delivery platform for enhancing oral bioavailability. Carbohydrate Polymers, 319. Scopus. https://doi.org/10.1016/j.carbpol.2023.121177

Siddiquee, R., Lo, V., Johnston, C. L., Buffier, A. W., Ball, S. R., Ciofani, J. L., Zeng, Y. C., Mahjoub, M., Chrzanowski, W., Rezvani-Baboli, S., Brown, L., Pham, C. L. L., Sunde, M., & Kwan, A. H. (2023). Surface-Induced Hydrophobin Assemblies with Versatile Properties and Distinct Underlying Structures. Biomacromolecules, 24(11), 4783–4797. Scopus. https://doi.org/10.1021/acs.biomac.3c00542

Sivasankaran, L. G., Rahim, S., & Sreenivasan, A. T. (2025). Synthesis and Anticancer Activity Evaluation of Self- assembled Curcumin Loaded Gelatin − Oleic acid – Carboxymethyl Chitosan Nanoparticles on MCF-7 cells. European Journal of Pharmaceutics and Biopharmaceutics, 211, 114718. https://doi.org/10.1016/j.ejpb.2025.114718

Sunita, Kaushik, R., Verma, K. K., & Parveen, R. (2025). Herbal Nanoformulations for Diabetes: Mechanisms, Formulations, and Clinical Impact. Current Diabetes Reviews, 21(3), e180324228072. https://doi.org/10.2174/0115733998288592240308073925

Teresia, V., Jie, L., & Jixiong, C. (202 C.E.). Interactive Learning Media Application For The Introduction Of Human Needs In Children Aged. Biomedical and Techno Nanomaterials, 1(1), 25–36. https://doi.org/10.55849/jsca.v1i1.406

Ünal, E. D., Duymaz, E., Kavukcu, S. B., Senthil, S., Türkmen, G., Başaran, B., & Türkmen, H. (2025). Novel water-soluble gelatin-based platinum nanoparticles for targeted cancer therapy with enhanced cytotoxicity. Journal of Nanoparticle Research, 27(1). Scopus. https://doi.org/10.1007/s11051-024-06212-y

Varaprasad, K., Sisubalan, N., Jayaramudu, T., & Yallapu, M. M. (2024). Nanocurcumin: A new and improved way to fight cancer and infections. Nano-Structures & Nano-Objects, 40, 101352. https://doi.org/10.1016/j.nanoso.2024.101352

Vidlářová, L., Romero, G. B., Hanuš, J., Štěpánek, F., & Müller, R. H. (2016). Nanocrystals for dermal penetration enhancement – Effect of concentration and underlying

mechanisms using curcumin as model. European Journal of Pharmaceutics and Biopharmaceutics, 104, 216–225. https://doi.org/10.1016/j.ejpb.2016.05.004

Wu, X., Hu, M., Cai, Y., Jia, F., Ye, Y., Yu, N., Chen, M., & Wang, K. (2025). Nano-based drug delivery systems for the treatment of non-infectious uveitis. Advances in Ophthalmology Practice and Research, 5(2), 124–134. https://doi.org/10.1016/j.aopr.2024.11.003